Stay updated with breaking news from Michaelk Schultz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumorsPreclinical data of VMT-??-NET demonstrated to significantly improve cell binding, tumor accumulation/retention
- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 - - Results indicate that MC1R-targeted
Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Announces Closing of Its Series A Financing with Proceeds of $13 Million ?? -NET into Phase 1 imaging studies beginning in 2021 and accelerate development of radioisotope production technologies CORALVILLE, IA / ACCESSWIRE / January 8, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, announced today it has closed the third and final tranche of its Series A financing for a t...